Strix – 2022 results, what’s “will prioritise debt reduction and free cash flow generation” actually likely to deliver?
Okyo Pharma – after the pump and dump now its a share support operation ahead of next bailout fund raise just weeks away
LoopUp – argues ‘a strong revenue run-rate heading into FY23’. Er, what about the bottom-line though?!
ShareProphets.com is run by authors who like writing about stocks.
There is no Mr Big telling our writers when to write or what to write they just submit content on stocks that they find interesting when they have something to say.
The writers are not paid to reach any conclusion but will just give their honest view of whether a share is expensive or cheap.
Keen to maintain high standards an editorial committee will accept applications from new writers only if they can demonstrate ability and integrity and years of market experience.
Writers can write about shares they own but must declare their holding and cannot tip a stock and sell before telling readers to sell and giving them a clear day to do so.
Our team of writers includes Steve Moore, Lucian Miers, Gary Newman, , Tom Winnifrith, Malcolm Stacey, Chris Bailey & Nigel Somerville.
All contributors to ShareProphets.com are freelance and are not employees of ShareProphets.com or any associated entity. Opinions and views are solely their own and do not reflect the opinions or views of ShareProphets.com or even each other.
Search ShareProphets |
Recent Comments |